Healthcare
AbbVie Inc.(ABBV)
Live Price
Offline$216.49
-2.14% today
1Y Change
+16.83%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $368.20B
- Revenue Growth
- +8.6%
- EPS Growth
- -1.2%
- Dividend Yield
- 3.2%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AbbVie Inc. (ABBV) is a Healthcare stock with a market cap of $368.20B and listed on NYSE. The stock last traded around $216.49 and up 16.8% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of -1.2%, a dividend yield of 3.2%. What stands out right now is revenue +8.6%, EPS -1.2%, free cash flow -0.1% with operating margin 27.6% and ROIC 10.6%. The dividend matters to the case here, with a current yield around 3.2%. Valuation already assumes a fairly strong business story at P/E 101.5 and price/sales 5.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ABBV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+8.6% vs +6.2% peer median
Operating Margin
Above sector median
+27.6% vs +10.1% peer median
P/E
Above sector median
101.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 24, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +8.6% and EPS is at -1.2%, with operating margin around 27.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 24, 2026 | โ | -0.7% | +4.0% | +8.6% |
2026 Feb 4, 2026 | +2.3% | +0.9% | +1.7% | +7.0% |
2025 Oct 31, 2025 | +5.1% | -2.8% | +0.5% | +3.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ABBV
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ABBV Max Drawdown
-19.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ABBV and SPY.
Company Overview
AbbVie Inc.
New York Stock Exchange
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Leadership
- Robert A. Michael
- IPO Date
- Jan 2, 2013
- Employees
- 55.0k
- Street Address
- 1 North Waukegan Road
- Mailing
- North Chicago, IL, 60064-6400
- Region
- North Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 847 932 7900
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 101.5
- EV/EBITDA
- 24.0
- Price/Sales
- 5.9
- Price/Book
- โ
Growth
- Revenue
- +8.6%
- EPS
- -1.2%
- Free Cash Flow
- -0.1%
Profitability
- Gross Margin
- 73.5%
- Operating Margin
- 27.6%
- Net Margin
- 5.8%
- ROE
- -311.4%
- ROIC
- 10.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.